Review date set for automated cervical screening:
This article was originally published in Clinica
Executive Summary
An FDA panel will meet on January 28 to vote on whether NeoPath's AutoPap system can be sold as a primary screening device for cervical cancer. The company submitted a PMA supplement in August with data on the system's ability to pick out smear slides that do not require manual review. The AutoPath would be the first commercially available automated screening device.